Preclinical, Publications Discovery and Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancer
Preclinical, Publications Two Pre-clinical Short Interfering RNA (siRNA) Molecules Targeting Human HSD17β13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Preclinical, Publications Discovery and Optimization of the Pre-Clinical Efficacy of Human PNPLA3-Targeting Short Interfering RNA Molecules (siRNAs) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Preclinical, Publications In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
Preclinical, Publications Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles
Preclinical, Publications Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs
Preclinical, Publications Class-A Cams Induce Cell Death Through HBV Core Protein Aggregation And Potentially Activate The Innate Immune Response
Preclinical, Publications Discovery of a Liver Targeted Oral PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
Preclinical, Publications Discovery of ALG-093989, a Highly Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancers
Preclinical, Publications Discovery of ALG-094103, a Liver-Targeted and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Liver Cancer